California State Teachers Retirement System Grows Holdings in Glaukos Corporation $GKOS

California State Teachers Retirement System boosted its position in shares of Glaukos Corporation (NYSE:GKOS) by 21.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 66,434 shares of the medical instruments supplier’s stock after acquiring an additional 11,871 shares during the period. California State Teachers Retirement System’s holdings in Glaukos were worth $7,152,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of GKOS. First Horizon Corp increased its stake in shares of Glaukos by 1,715.4% in the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 223 shares in the last quarter. Los Angeles Capital Management LLC purchased a new position in shares of Glaukos during the 4th quarter valued at $28,000. Larson Financial Group LLC lifted its stake in shares of Glaukos by 62.0% during the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after buying an additional 132 shares in the last quarter. Parallel Advisors LLC boosted its holdings in Glaukos by 159.2% in the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 226 shares during the period. Finally, Farther Finance Advisors LLC boosted its holdings in Glaukos by 111.4% in the 4th quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock worth $46,000 after buying an additional 215 shares during the period. 99.04% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Stifel Nicolaus raised their price target on Glaukos from $175.00 to $190.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Piper Sandler reaffirmed an “overweight” rating and issued a $195.00 price objective (up from $165.00) on shares of Glaukos in a research note on Thursday, July 30th. UBS Group began coverage on Glaukos in a research report on Tuesday, July 28th. They set a “neutral” rating and a $150.00 target price for the company. JPMorgan Chase & Co. lifted their target price on Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Finally, BTIG Research boosted their price target on Glaukos from $164.00 to $193.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Twelve research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $177.33.

Insider Transactions at Glaukos

In other news, Director Leana Wen sold 525 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $167.63, for a total value of $88,005.75. Following the completion of the sale, the director directly owned 21,092 shares of the company’s stock, valued at $3,535,651.96. This trade represents a 2.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Gilbert H. Kliman sold 5,000 shares of Glaukos stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $140.76, for a total value of $703,800.00. Following the completion of the transaction, the director owned 35,528 shares of the company’s stock, valued at approximately $5,000,921.28. This trade represents a 12.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 40,525 shares of company stock worth $6,116,806 in the last three months. Insiders own 5.90% of the company’s stock.

Glaukos Trading Up 0.0%

Shares of Glaukos stock opened at $170.60 on Thursday. The firm has a market cap of $10.06 billion, a price-to-earnings ratio of -52.49 and a beta of 0.78. The business has a 50-day moving average price of $141.42 and a 200-day moving average price of $126.46. The company has a quick ratio of 4.46, a current ratio of 5.04 and a debt-to-equity ratio of 0.10. Glaukos Corporation has a twelve month low of $73.16 and a twelve month high of $184.00.

Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. The company had revenue of $185.61 million for the quarter, compared to the consensus estimate of $150.93 million. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The firm’s revenue for the quarter was up 49.6% on a year-over-year basis. During the same period in the previous year, the business earned ($0.24) earnings per share. Equities research analysts anticipate that Glaukos Corporation will post -0.35 EPS for the current fiscal year.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.